PYPD Stock Overview
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
PolyPid Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$4.60 |
52 Week High | US$14.10 |
52 Week Low | US$3.57 |
Beta | 1.41 |
1 Month Change | -16.21% |
3 Month Change | -33.33% |
1 Year Change | -64.34% |
3 Year Change | -98.43% |
5 Year Change | n/a |
Change since IPO | -99.19% |
Recent News & Updates
Recent updates
PolyPid set to cut 20% jobs
Oct 20PolyPid's surgical site infections treatment eligible for marketing nod submission in EU
Sep 28PolyPid sheds 75% as lead candidate fails in Phase 3 trial for post-surgical infections
Sep 02PolyPid GAAP EPS of -$1.23 misses by $0.60
Aug 10PolyPid to get $2.6M upfront under license deal with Advanz for D-PLEX in Europe
Aug 03PolyPid: Strong Pipeline, Close Catalysts
Apr 19Will PolyPid (NASDAQ:PYPD) Spend Its Cash Wisely?
Mar 18Here's Why We're Watching PolyPid's (NASDAQ:PYPD) Cash Burn Situation
Nov 08We Think PolyPid (NASDAQ:PYPD) Can Afford To Drive Business Growth
Jul 15Here's Why We're Not Too Worried About PolyPid's (NASDAQ:PYPD) Cash Burn Situation
Mar 09PolyPid's oncoplex cancer program shows encouraging action in animal study
Dec 22PolyPid launches second late-stage trial with D-PLEX100 in surgical infections
Dec 16PolyPid pops 24% after D-PLEX100 nabs accelerated review in U.S. for preventing surgical infections
Nov 24Shareholder Returns
PYPD | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 2.2% | -3.1% | -1.7% |
1Y | -64.3% | 11.5% | 22.4% |
Return vs Industry: PYPD underperformed the US Pharmaceuticals industry which returned 11.5% over the past year.
Return vs Market: PYPD underperformed the US Market which returned 22.4% over the past year.
Price Volatility
PYPD volatility | |
---|---|
PYPD Average Weekly Movement | 13.1% |
Pharmaceuticals Industry Average Movement | 9.5% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PYPD's share price has been volatile over the past 3 months.
Volatility Over Time: PYPD's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 61 | Dikla Czaczkes Akselbrad | www.polypid.com |
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer.
PolyPid Ltd. Fundamentals Summary
PYPD fundamental statistics | |
---|---|
Market cap | US$22.07m |
Earnings (TTM) | -US$23.86m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs PYPD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PYPD income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$23.87m |
Earnings | -US$23.86m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -4.97 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | -495.3% |
How did PYPD perform over the long term?
See historical performance and comparison